Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Executive Summary

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.


Related Content

Monat Offensive Fails To Deter Class Actions For Alleged Fraud, Hair Loss
'FDA' Link In Rodan + Fields Prop 65 Warning Now Goes To The Agency
Beiersdorf Moves To Squash Suit Alleging NIVEA Firming Lotion Is An Unapproved Drug
Supreme Court Turns Down Athena v. Allergan; 'Torrent' Of Suits To Come?
Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims
FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims
Jan Marini Explores Anti-Aging Hair-Care Frontier With Revamped Conditioner
Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts